To the best of our knowledge, octreotide, concerning AKI, had its possible renoprotective effect evaluated only in Hepatic ischemia and reperfusion injury (HIR), where it was shown to reduce kidney damage after HIR due to deactivation of the protein kinase B (Akt)-mammalian target of rapamycin (mTOR) pathway and reduction of renal inflammation and apoptosis (Sun et al., 2017). The gene discussed is MTOR; the disease is acute kidney injury.